Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study. by Chamali, B et al.
www.irdrjournal.com
Intractable & Rare Diseases Research. 2016; 5(2):109-113. 109
Dietary supplement use and nosebleeds in hereditary haemorrhagic 
telangiectasia ‒ an observational study
Basel Chamali1,2, Helen Finnamore1,3, Richard Manning4, Michael A Laffan4,5, Mary Hickson6, 
Kevin Whelan3, Claire L Shovlin1,7,*
1 National Heart and Lung Institute Cardiovascular Sciences, Imperial College London, UK;
2 Imperial College School of Medicine, Imperial College London, UK;
3 Diabetes and Nutritional Sciences Division, King's College London,  UK;
4 Haematology Department, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK;
5 Centre for Haematology, Imperial College London, UK
6 Nutrition and Dietetics, Imperial College Healthcare NHS Trust, London, UK (Current address: School of Health Professions, 
Plymouth University, Plymouth, UK);
7 HHTIC London,  Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
1. Introduction
Patients with hereditary haemorrhagic telangiectasia 
(HHT) provide an intriguing real-life model to 
evaluate potential precipitants of haemorrhage. 
Due to a causative mutation most commonly in an 
ENG, ACVRL1 or SMAD4 gene, HHT leads to the 
development of vascular abnormalities, particularly 
visceral arteriovenous malformations, and smaller nasal 
and gastrointestinal telangiectasia (1,2). Patients with 
HHT can report nosebleeds (epistaxis) in real time, and 
the magnitude of their nasal haemorrhagic losses are 
such that iron deficiency anaemia commonly results, 
permitting objective evaluations (3).
 Understanding nosebleed precipitants is also 
important in the overall management of people with 
HHT. Despite a battery of potential interventional, 
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surgical, and medical approaches (4), HHT patients 
are commonly iron deficient and/or anaemic because 
replacing iron lost through recurrent haemorrhage 
demands very high iron intakes (3). In a recently 
surveyed international group, 273 of 1,288 (21.2%) had 
received iron infusions and 396 (30.8%) had received 
blood transfusions, 105 (8.1%) on at least 10 occasions 
(5). Additionally, arterial rate bleeds can cause acute 
haemodynamic disturbances (3,4,6,7); epistaxis severity 
is a major predictor of reduced quality of life (8-11); 
and epistaxis is the primary outcome measure in nine of 
ten clinical trials of new therapeutic agents recruiting in 
HHT (12).
 Understanding what provokes HHT nosebleeds 
at particular times offers insights into haemorrhagic 
precipitants, and potential strategies to limit healthcare 
demands, improve quality of life, and optimise clinical 
trial design. HHT nosebleeds are highly variable, and 
generally difficult to predict. However, in recent studies 
by our group, HHT patients reported that nosebleeds 
could be precipitated by certain food groups (13,14). 
Spontaneously volunteered precipitant foods included 
red wine, spices, chocolate, coffee, berries, oily 
fish, and other food items that contain high levels of 
naturally occurring salicylates and other anti-platelet 
agents (13). We hypothesised that for some people, 
suggesting dietary changes may also detrimentally 
impact on their quality of life, and therefore examined 
nosebleed relationships with dietary supplements that 
may be more readily modified. 
2. Materials and Methods
2.1. Ethics
The study was given a favourable Ethics opinion by the 
London Wandsworth Research Ethics Committee (11/
H0803/8), and all participants gave written informed 
consent.
2.2. Survey methodology
Based on previous experience from pilot study 
numbers, an unselected group of 50 patients with HHT 
attending our tertiary care clinic were recruited into a 
blood sample and questionnaire-based study during two 
study periods to coincide with recruiter availability, 
April-September 2011, and March-May 2013. Inclusion 
criteria were a definite diagnosis of HHT using the 
Curaçao Criteria (15) and not residing in the same 
household as another study participant. Within this 
period, ~180 eligible patients were approached by 
letter or in person. All recruited participants recorded 
nosebleed severity by the validated Epistaxis Severity 
Score (ESS) (16). This rates nosebleed severity on a 
scale of 0-10, with the minimal important difference 
recently identified as 0.71 (17). Dietary supplement 
intake was assessed in an unbiased manner on the 
final page of the validated European Prospective 
Investigation into Cancer and Nutrition (EPIC) Food 
Frequency Questionnaire (18). Participants were asked 
"Have you taken any vitamins, mineral, fish oils, fibre 
or other food supplements during the past year?" and 
then asked to detail the brand, strength, amount and 
frequency (6 frequency options were provided).
2.3. Haematological evaluations
Blinded to epistaxis severity scores and supplement use, 
full blood count, prothrombin time (PT), activated partial 
thromboplastin time (APTT), fibrinogen concentrations, 
and biochemical analyses were measured as part of 
routine clinical care. Blood samples were obtained by a 
professional phlebotomist in the early to mid-afternoon, 
and centrifuged to obtain platelet-rich plasma (PRP) 
and platelet poor plasma (PPP). Blinded to supplement 
use and other blood results, PRP was used to determine 
platelet aggregation to freshly-prepared adenosine 
diphosphate (ADP), by a Helena Aggregometer.
2.4. Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 6 (GraphPad Software, San Diego, CA). 
Participants were categorised by supplement use as 
described in the text. Where there were three categories 
(e.g. no supplement use, iron supplement, and non iron 
supplement use; or no supplement use, fish oil and non 
fish oil supplement use) p values were calculated using 
Kruskal Wallis. Where there were two categories (e.g. 
supplements use, or no use of supplements), p values 
were calculated using Mann Whitney.
3. Results and Discussion
The 50 study participants ranged in age from 18 to 72 
(median 53) years with an even gender distribution. 
Haemoglobin ranged from 5.9 to 17.8 (median 14.1) g/
dL, with higher values in participants with hypoxaemia 
(low blood oxygen levels) induced by pulmonary 
arteriovenous malformations (19) that affect at least 
50% of people with HHT (20).
 Of the 50 participants, 24 (48%) had used dietary 
supplements in the previous year. Twelve of the HHT-
affected study participants used iron supplements 
which would be fully appropriate given their high iron 
requirements, but 18/50 (36%) also used between 1-3 
non-iron containing supplements (Figure 1). There 
were no evident gender differences, but compared to 
the 26 study participants using no supplements (median 
age 53, IQR 40, 63 years), there were trends for iron 
supplement users to be younger (median age 47, IQR 
39.5, 62.3 years) and non-iron supplement users to be 
older (median age 58.5, IQR 49.5, 66 years).
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severity scores did not differ between users of fish 
oils and any other group (data not shown). However, 
subtle differences emerged examining indices related 
to platelets in blood from fish oil users compared to 
non users of fish oils. Platelet counts were lower in 
supplement users (p = 0.037, Figure 4A), while serum 
fibrinogen, which can act as a circulating protein for 
platelet aggregation (Figure 4B), also tended to be 
lower in fish oil supplement users (p = 0.07). For a 
subgroup of 11 patients, 'selected' based purely on 
dates of attendance at clinic when the study was in 
progress, platelet aggregation studies were undertaken 
and provided provocative, preliminary findings: Within 
this very small sample, although there was no apparent 
difference in platelet aggregation to ADP between iron/
 The cohort demonstrated the full spectrum of 
nosebleed severity with epistaxis severity scores 
ranging from 0 (none) to 9.1 out of 10 (median 3.9; IQR 
2.5, 5.0). The highest ESS of 9.1 was observed in two 
supplement users- one used fish oil and vitamins, and 
one used iron (Figure 2A). Overall, HHT patients with 
more nosebleeds tended to use iron supplements: the 
median ESS in the 38 non-iron users combined was 3.2 
(IQR 1.8, 4.8) compared to 4.7 (IQR 4.0-5.2) in the 12 
iron supplement users (p = 0.012 by Mann Whitney).
 The difference in nosebleeds between the iron and 
non-iron using HHT cohorts substantially exceeded 
the minimal important difference for the epistaxis 
severity score (17), and corresponded to the difference 
between one nosebleed per week, typically lasting 1 
to 5 minutes, and an average of one a day, typically 
lasting 6-15 minutes (16). For a male, the haemorrhage-
adjusted i ron requirement  (HAIR) (3 )  would 
increase from 9.1 to 35 mg/day, compared to the UK 
recommended nutrient intake (RNI) of 8.7 mg of iron 
per day (21).
 However, the HHT patients using iron supplements 
had higher serum iron concentrations than the other 
study participants (Figure 2B), and despite their more 
frequent nosebleeds, were able to maintain their red 
blood cell indices (Figure 3). There was no discernable 
trend in mean corpuscular volume (MCV) or mean 
corpuscular haemoglobin (MCH), indices that are 
generally unaffected by the secondary erythrocytosis 
observed in hypoxaemic patients with PAVMs (19). 
There were only possible trends towards lower 
haemoglobin and haematocrit values (Figure 3).
 As noted in Figure 1, 18/50 (36%) study participants 
used non-iron containing supplements. These were 
most commonly vitamins (N = 15) or fish oil (N = 8), 
and included glucosamine, coenzyme Q10, alpha lipoic 
acid, echinacea, magnesium, and evening primrose. The 
one individual using echinacea had stopped taking it, 
because it seemed to make their nosebleeds worse.
 Fish oil supplements are known to have anti-platelet 
activity (22-25). In the cohort as a whole, epistaxis 
Figure 1. Dietary supplement use by 50 HHT patients. 
Venn diagram indicating overlapping use of dietary 
supplements, with circles to scale according to number of 
participants ingesting the item in the previous year. 
Figure 2. Nosebleeds and serum iron, categorised by 
dietary supplement use. (A) Epistaxis severity score (ESS): 
The ESS ranges from zero (no nosebleeds) to 10. As outlined 
in Figure 1, the non iron supplements comprised vitamins (N = 
15), fish oil (N = 8), glucosamine, coenzyme Q10, alpha lipoic 
acid, echinacea, magnesium, and evening primrose. Median 
values indicated. 3 group comparison, p = 0.075 by Kruskal 
Wallis. (B) Serum iron in the 50 study participants. Note that 
the institutional normal range is 7-27 µmol/L. Median values 
indicated. Overall Kruskal Wallis p-value = 0.033. Data from 
all 50 study participants.
Figure 3. Red blood cell indices, categorised by dietary 
supplement use. (A) Haemoglobin (Hb, Kruskal Wallis p = 
0.41); (B) Haematocrit (Kruskal Wallis p = 0.62); (C) Mean 
corpuscular volume (MCV, Kruskal Wallis p = 0.69); (D) 
Mean corpuscular haemoglobin concentration (MCH, Kruskal 
Wallis p = 0.66). Median and interquartile range indicated. 
Data from all 50 study participants.
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other vitamins, and non supplement users (Figure 4C), 
the one individual using fish oil demonstrated markedly 
reduced platelet aggregation to ADP (Figure 4C). 
The strengths of the study were the use of validated 
questionnaires to capture epistaxis severity and 
dietary supplement intake, and the evaluation of a 
patient population able to recognise and report their 
haemorrhagic losses in a quantifiable manner. It is clearly 
a small study that should be repeated in larger HHT 
cohorts, and the observational nature means it is difficult 
to infer causality, but we believe it does allow helpful 
conclusions to be drawn.
 First, it was surprisingly common for people 
with HHT to use dietary supplements. The non-iron 
supplements were generally instituted by the patients 
themselves. The supplements were not recorded on 
communications to us, and we suspect, were not 
recognised within standard clinical care pathways.
 Second, the supplements which were self-prescribed 
included fish oils with recognised anti-platelet activity. 
The study participants appeared to demonstrate subtle 
differences in platelet activity, although differences in 
epistaxis scores did not emerge in the small cohorts. 
High proportions of HHT patients avoid therapeutic 
antiplatelet and anticoagulant agents, often on medical 
advice (26). It is not known whether any potential anti-
platelet activity for example, from Omega-3 compounds 
(22-25), would be sufficient to exacerbate HHT 
nosebleeds in the subgroup of individuals who report 
that their HHT nosebleeds are exacerbated by aspirin 
and/or clopidogrel (26). We are however, unaware of any 
medical recommendation for their use in haemorrhagic 
disorders, and in the clinic, find patients to be surprised 
and concerned that these "healthy supplements" may 
act as natural blood thinners.
 Third, within this small observational sample, 
despite having worse nose bleeds, iron supplement 
users had higher serum iron than non iron users, and 
were able to maintain their baseline haemoglobin and 
red cell indices. This would support data from other 
sources suggesting oral iron absorption is appropriate in 
people with HHT (i.e. enhanced in iron-deficiency (3)). 
It may be of concern however, that for five iron users, 
serum iron concentrations were at least twice the upper 
limit of normal (Figure 2B), in keeping with recent 
data from a healthy volunteers study (5). One in 20 
HHT iron users report nosebleeds are worse after iron 
treatments (5,27), and recent data suggest one plausible 
biological explanation through activation of endothelial 
DNA damage response pathways by 10 µM iron (28), 
an order of magnitude lower than examined in recent 
iron toxicity studies (29,30).
 In conclusion, this study highlights how frequently 
people  wi th  HHT sel f -medicate  wi th  d ie tary 
supplements that may influence nosebleed (epistaxis) 
severity and platelet function. The scale of use, and 
potential of "natural health supplements" to exacerbate 
nosebleeds has not been appreciated previously in HHT. 
We suggest management of people with HHT and other 
haemorrhagic disorders should include a discussion 
of dietary supplements, and particularly the fish oil 
supplements that have recognised antiplatelet activity 
(22-25). For individuals with troublesome haemorrhage 
or iron deficiency, a trial of cessation of non-iron 
containing supplements may be indicated unless there 
has been clear benefit from their use.
Acknowledgements
This study received support from the National Heart 
and Lung Institute's BSc Project Funds (for B.C.), 
King's College London (for H.F.), and donations from 
families and friends of HHT patients. The authors also 
acknowledges support from the NIHR Biomedical 
Research Centre Funding Scheme (Imperial BRC). 
The funders played no role in the design or conduct 
of the study; collection, management, analysis, or 
interpretation of the data; preparation, review, or 
approval of the manuscript; or decision to submit the 
manuscript for publication. We thank Gillian Angus 
for advice on platelet aggregation measurements, and 
the patients for their willing participation in these 
studies.
Figure 4. Coagulation and platelet aggregation. (A) Platelet counts and (B) Fibrinogen concentrations, in the 50 study participants, 
categorised by supplement use, median values indicated. There was no apparent difference in routine coagulation screens (prothrombin 
time, activated partial thromboplastin time, data not shown). (C) Platelet aggregation to stated concentrations of adenosine diphosphate 
(ADP) in the subgroup of 11 participants undergoing platelet aggregation studies, categorised by ingestion of no supplements ('None', 
N = 7), supplements other than fish oil ('non fish', N = 3), and fish oil (N = 1).  Means and standard deviations illustrated.
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